Related Experiment Video
Updated: Jan 5, 2026
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
54.3K
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis
Christopher L Bowlus1, Paul J Pockros2, Andreas E Kremer3
1Division of Gastroenterology and Hepatology, University of California Davis, Sacramento, California.
Summary
Long-term obeticholic acid (OCA) treatment improved or stabilized liver fibrosis and other histologic features in patients with primary biliary cholangitis (PBC). This study highlights OCA
Area of Science:
- Hepatology
- Autoimmune Diseases
- Fibrosis Research
Background:
- Primary biliary cholangitis (PBC) is an autoimmune liver disease causing bile duct destruction and potential cirrhosis.
- The POISE study evaluated obeticholic acid (OCA) in PBC patients intolerant or unresponsive to ursodeoxycholic acid.
Purpose of the Study:
- To assess the long-term effects of OCA on liver damage and fibrosis in PBC patients.
- To analyze liver biopsy substudy data from the POISE trial.
Main Methods:
- Liver biopsies from 17 PBC patients were analyzed before and after 3 years of OCA treatment.
- Histologic evaluations and quantitative collagen morphometry using advanced microscopy were performed.
Main Results:
- Most patients showed improvement or stabilization in fibrosis, bile duct loss, and inflammation markers.
- Significant reductions were observed in collagen area ratio, fiber density, reticulation index, and fibrosis composite score (P < .05).
Conclusions:
- Long-term OCA treatment demonstrated improvements in liver histology and fibrosis in PBC patients.
- OCA shows potential for managing liver damage and fibrosis in this autoimmune condition.
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
716
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
716
01:29Chronic Pancreatitis II: Collaborative Care
279
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
279
01:21Drugs for Treatment of Constipation-Predominant IBS
662
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
662
01:24Chronic Pancreatitis I: Introduction
642
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
642
01:29Inflammatory Bowel Disease IV: Pharmacological Management
420
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
420
01:29Drugs for Treatment of Ulcerative Colitis in IBD
409
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
409